Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

Roschitz, B; Beitzke, A; Gamillscheg, A; Sudi, K; Koestenberger, M; Leschnik, B; Muntean, W.
Signs of thrombin generation in pediatric cardiac catheterization with unfractionated heparin bolus or subcutaneous low molecular weight heparin for antithrombotic cover.
Thromb Res. 2003; 111(6):335-341 Doi: 10.1016%2Fj.thromres.2003.09.020
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Führende Autor*innen der Med Uni Graz
Acham-Roschitz Birgit
Muntean Eugen
Co-Autor*innen der Med Uni Graz
Beitzke Albrecht
Gamillscheg Andreas
Koestenberger Martin
Leschnik Bettina
Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:
INTRODUCTION: Thrombosis is one of the most frequent adverse events after cardiac catheterization, which can be reduced by anticoagulation with unfractionated heparin (UFH) in both children and adults. Low molecular weight heparin (LMWH) might possibly offer advantages. Laboratory signs of thrombin generation during pediatric cardiac catheterization, with unfractionated heparin (UFH) bolus or subcutaneous LMWH for thrombosis prophylaxis, were determined in a first step to investigate the potential of LMWH for antithrombotic cover. MATERIALS AND METHODS: Signs of thrombin generation (D-dimer and F1+2), anti-Xa activity and activated clotting time (ACT) were measured in 65 patients with congenital heart disease. A total of 40 patients were treated with a UFH bolus of 100 IU/kg bodyweight and, in 25 children, enoxaparin was subcutaneously administered at a dosage of 1/1.6 mg/kg bodyweight. RESULTS: The dose to plasma activity of enoxaparin was more consistent than in the UFH group. Only a slight elevation of F1+2 was found in some patients, which was a little higher in the enoxaparin group, but no difference of incidence of increased F1+2 generation was detected between the two groups. D-dimer was elevated in three children after UFH bolus application, but no such effect was observed in any child after LMWH administration. CONCLUSIONS: Application of LMWH was equally efficacious during pediatric cardiac catheterization than UFH bolus administration, as determined by plasma levels and markers of clotting activation. In contrast to UFH bolus, no further monitoring was necessary after the application of LMWH during cardiac catheterization due to a consistent dose to plasma activity.
Find related publications in this database (using NLM MeSH Indexing)
Adolescent -
Anticoagulants - administration and dosage
Child - administration and dosage
Child, Preschool - administration and dosage
Female - administration and dosage
Heart Catheterization - adverse effects
Heparin - administration and dosage
Heparin, Low-Molecular-Weight - administration and dosage
Humans - administration and dosage
Infant - administration and dosage
Injections, Subcutaneous - administration and dosage
Male - administration and dosage
Thrombin - biosynthesis
Thromboembolism - prevention and control

Find related publications in this database (Keywords)
cardiac catheterization
pediatrics
anticoagulation
unfractionated heparin
low molecular weight heparin
© Med Uni Graz Impressum